Investor Relations

<< Back

Press Release

September 4, 2019 at 4:05 PM EDT

Anika Therapeutics to Host Analyst and Investor Day on September 18, 2019

BEDFORD, Mass.--(BUSINESS WIRE)--Sep. 4, 2019-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced that it will host an Analyst and Investor Day on Wednesday, September 18, 2019 from 9:00 a.m. to 11:30 a.m. ET in Boston, MA.

Anika’s leadership team will provide updates on its transformation into a global commercial company and highlights from the Company’s 5-year strategic plan. Additionally, they will be joined by the following world leading clinicians to provide insights about current and potential new treatments in orthopedic and regenerative medicine.

  • Mohit Bhandari, MD, Ph.D., FRCSC, Professor, Orthopaedic Surgery at McMaster University
  • Timothy Deakon, MD, Orthopaedic Surgeon, Director of the Oakville Sports Injury Clinic
  • Kevin Plancher, MD, FAAD, Orthopaedic Surgeon, Plancher Orthopaedics & Sports Medicine
  • Konrad Slynarski, MD, Ph.D., Orthopaedic Surgeon, President of the Polish Arthroscopy Society
  • John Tierney, DO, Orthopaedic Surgeon, President of the Greater Boston Orthopaedic Center

A live audio webcast of the event may be accessed via the “Investor Relations” section of Anika’s website at An audio archive of the webcast also will be available on the website.

About Anika Therapeutics, Inc.

Anika Therapeutics, Inc.(NASDAQ: ANIK) is a global, integrated orthopedic and regenerative medicines company based in Bedford, Massachusetts. Anika is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies along the continuum of care, from palliative pain management to regenerative tissue repair. The Company has over two decades of global expertise developing, manufacturing, and commercializing more than 20 products based on its proprietaryhyaluronic acid (HA) technology. Anika's orthopedic medicine portfolio includesORTHOVISC®,MONOVISC®, andCINGAL®, viscosupplements which alleviate pain and restore joint function by replenishing depleted HA, andHYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration. For more information about Anika, please

Source: Anika Therapeutics, Inc.

For Investor Inquiries:
Anika Therapeutics, Inc.
Sylvia Cheung, 781-457-9000
Chief Financial Officer

For Media Inquiries:
Pure Communications
Sonal Vasudev, 917-523-1418